The pharmaceutical sector has witnessed a massive financial breakthrough as GlaxoSmithKline Pakistan Limited, or GSK, released its 2025 annual results. The company reported a staggering profit after taxation of Rs 10.025 billion. This figure represents a 53.4 percent increase from the Rs 6.536 billion recorded in 2024. Revenue from contracts also saw a healthy climb to Rs 65.9 billion. This 7.7 percent rise in net sales highlights the company’s resilient market position. Efficient cost management allowed operating profit to surge by 56.2 percent during the same period.
Why the Massive GSK Dividend Payout Benefits PSX Investors
The latest earnings per share jumped to Rs 31.48, marking exceptional value creation for shareholders. Because of this performance, GSK announced a final cash dividend of Rs 12 per share. When added to the previous interim dividend, this brings total payouts to a significant level for the year. Gross profit reached Rs 24.384 billion, which indicates very strong pricing power. The company’s ability to manage its product mix successfully has resulted in gross profit growth of 58.4 percent. These numbers demonstrate a clear operational leverage where profit growth far exceeds revenue growth.
For mutual fund holders, these results offer a significant boost to pharmaceutical-themed portfolios. The 120 percent dividend payout reflects deep management confidence in sustained profitability for 2026. Investors should monitor quarterly results to track continued momentum in the healthcare sector. The company’s focus on operational efficiency has clearly paid off, setting a high benchmark for the industry. This performance reinforces the role of high-quality pharmaceutical stocks in providing both growth and consistent income.
The substantial improvement in earnings per share demonstrates a clear path toward long-term wealth generation. As the healthcare sector evolves, the company’s strong portfolio management remains a key differentiator. Market share trends suggest that the brand continues to dominate essential medicine categories across Pakistan. Investors looking for stability and high yields will likely find these audited results highly encouraging.
PSX Pharmaceutical Sector 2025 Performance Comparison
The data reflects the final audited results for the year ended December 31, 2025 (CY2025).
| Company | Profit After Tax (PKR Bn) | Profit Growth (%) | EPS (PKR) | Dividend (PKR) |
| GSK Pakistan | 10.02 | 53.4% | 31.48 | 17.00* |
| Abbott Pakistan | 6.81 | 23.0% | 53.46 | 10.00 |
| AGP Limited | 3.80 | 46.0% | 13.34 | 6.00 |
| Searle Company | 0.43 | Recovery** | 0.85 | 2.50 |
| Ferozsons | 1.84 | 18.0% | 12.20 | 4.00 |
Key Takeaways for PSX Investors
- Growth Leader: GSK Pakistan leads the “Big Pharma” category with 53.4% profit growth, significantly outperforming Abbott’s 23%.
- Dividend Yield: GSK’s total payout of Rs 17 per share makes it one of the highest-yielding blue-chip stocks in the sector for 2026.
- Operational Efficiency: While Abbott maintains a higher absolute Earnings Per Share (EPS), GSK’s growth trajectory suggests superior cost management and pricing power following the 2024 deregulation of non-essential drugs.
- Sector Trend: The 34% surge in industry-wide exports during 2025 has provided a strong tailwind for companies like AGP and Ferozsons, which are aggressively expanding their footprint in Central Asian markets.
